Evrysdi has ‘real world impact’ on lives of babies with severe SMA, says RocheRoche’s Genentech unit has released further data from a key trial of Evrysdi, its oral treatment for spinal Share XEvrysdi has ‘real world impact’ on lives of babies with severe SMA, says Rochehttps://pharmaphorum.com/news/evrysdi-has-real-world-impact-on-lives-of-babies-with-severe-sma-says-roche/
Romark eyes FDA okay for COVID antiviral despite mixed trial resultsA phase 3 trial of Romark’s antiviral drug NT-300 has missed the main objective in a phase 3 Share XRomark eyes FDA okay for COVID antiviral despite mixed trial resultshttps://pharmaphorum.com/news/romark-eyes-fda-okay-for-covid-antiviral-despite-mixed-trial-results/
Pfizer/Myovant take relugolix contraceptive combination pill into phase 3Pfizer and Myovant have begun a late-stage trial of their potential uterine fibroid drug relugolix, as part of Share XPfizer/Myovant take relugolix contraceptive combination pill into phase 3https://pharmaphorum.com/news/pfizer-myovant-take-relugolix-contraceptive-combination-pill-into-phase-3/
Race for hepatitis B drug intensifies as Antios raises $96m for phase 2 trialAntios has raised $96 million in Series B financing to support the ongoing phase 2 development of its Share XRace for hepatitis B drug intensifies as Antios raises $96m for phase 2 trialhttps://pharmaphorum.com/news/race-for-hepatitis-b-drug-intensifies-as-antios-raises-96m-for-phase-2-trial/
Akari begins late-stage trial of nomacopan for Bullous PemphigoidAkari Therapeutics is to begin a late-stage trial of nomacopan, its potential therapy for Bullous Pemphigoid, the rare Share XAkari begins late-stage trial of nomacopan for Bullous Pemphigoidhttps://pharmaphorum.com/news/akari-begins-late-stage-trial-of-nomacopan-for-bullous-pemphigoid/
South African variant may evade Pfizer/BioNTech vaccine, study findsThe coronavirus variant discovered in South Africa may evade Pfizer/BioNTech’s vaccine, according to a real-world data study conducted Share XSouth African variant may evade Pfizer/BioNTech vaccine, study findshttps://pharmaphorum.com/news/south-african-variant-may-evade-pfizer-biontech-vaccine-study-finds/
Regeneron’s antibody cocktail hits target in COVID prevention studyRegeneron is to ask the FDA for clearance to use its antibody cocktail as a preventive treatment for Share XRegeneron’s antibody cocktail hits target in COVID prevention studyhttps://pharmaphorum.com/news/regeneron-to-ask-fda-to-c/
AstraZeneca’s Farxiga fails phase 3 COVID-19 testHope that AstraZeneca’s diabetes and heart failure drug Farxiga might treat patients hospitalised with COVID-19 have been dashed Share XAstraZeneca’s Farxiga fails phase 3 COVID-19 testhttps://pharmaphorum.com/news/astrazenecas-farxiga-fails-phase-3-covid-19-test/
Sanofi licences in potential oral IL-17 drug from UK’s C4X DiscoverySanofi has licensed a potential inflammatory diseases drug from Manchester University spin-off C4X Discovery Holdings in a deal Share XSanofi licences in potential oral IL-17 drug from UK’s C4X Discoveryhttps://pharmaphorum.com/news/sanofi-licences-in-potential-oral-il-17-drug-from-uks-c4x-discovery/